Cargando…

“Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients”

BACKGROUND: Comparative effectiveness research has recently attracted considerable attention. The Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) is an ongoing prospective cohort study of adult patients with Rheumatoid Arthritis (RA). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pappas, Dimitrios A, Kremer, Joel M, Reed, George, Greenberg, Jeffrey D, Curtis, Jeffrey R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978136/ https://www.ncbi.nlm.nih.gov/pubmed/24690143 http://dx.doi.org/10.1186/1471-2474-15-113

Ejemplares similares

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
por: Harrold, Leslie R, et al.
Publicado: (2014)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
por: Mease, Philip J., et al.
Publicado: (2019)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
por: Winthrop, Kevin L, et al.
Publicado: (2021)

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
por: Mease, Philip J, et al.
Publicado: (2019)

Malignancy validation in a United States registry of rheumatoid arthritis patients
por: Fisher, Mark C, et al.
Publicado: (2012)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry
por: Mease, Philip J., et al.
Publicado: (2018)

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry
por: Mease, Philip J., et al.
Publicado: (2018)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk
por: Yarwood, Annie, et al.
Publicado: (2015)

Rationale and Design of the Orencia Atherosclerosis and Rheumatoid Arthritis Study (ORACLE Arthritis Study): Implications of Biologics against Rheumatoid Arthritis and the Vascular Complications, Subclinical Atherosclerosis
por: Ishigami, Tomoaki, et al.
Publicado: (2021)

Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study
por: Nowell, William Benjamin, et al.
Publicado: (2019)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs
por: Thomas, Konstantinos, et al.
Publicado: (2017)

Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey
por: Pappas, Dimitrios A., et al.
Publicado: (2022)

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
por: Pappas, Dimitrios A, et al.
Publicado: (2021)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
por: Reed, George W., et al.
Publicado: (2017)

Hydroxychloroquine and the risk of respiratory infections among RA patients
por: Kremer, Joel M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_klnhpi5121lj7l2bvi059oc0fj